ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.1
  1. ホーム
  2. /化合物

こはく酸スマトリプタン

Sumatriptan Succinate

HCID 59772
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
103628-48-4
標準SMILES
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O
InChIKey
PORMUFZNYQJOEI-UHFFFAOYSA-N
分子式
C18H27N3O6S
平均分子量
413.5 g/mol
単同位体質量
413.16205676

概要

Sumatriptan succinate is a succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatment of migraine with or without aura in adults. It has a role as a serotonergic agonist and a vasoconstrictor agent. It contains a sumatriptan(1+).

名称と識別子

優先名称
Sumatriptan Succinate
IUPAC
butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
現地名
こはく酸スマトリプタン
英語名
Sumatriptan succinate
分子式
C18H27N3O6S
分子量
413.48848

名称と別名

SUMATRIPTAN SUCCINATE103628-48-4Sumavel DoseProAlsumaOnzetra XsailImitrex StatdoseGR 43175CZembrace SymTouchSumatriptan GalpharmSumatriptan (as succinate)GR-43175CNSC-760362
名称をさらに表示
こはく酸スマトリプタン3-[2-(ジメチルアミノ)エチル]-1H-インドール-5-イル-N-メチルメタンスルホンアミドこはく酸塩スマトリプタンコハク酸塩スマトリプタンコハク酸塩 (JAN)スマトリプタン・こはく酸スマトリプタン・こはく酸塩イミグランスマトリプタンスクシナートN-メチル-[3-[2-(ジメチルアミノ)エチル]-1H-インドール-5-イル]メタンスルホンアミド・こはく酸SuMitrexgr43175cSumatriptan succinatSuccinate Sumatriptanmethanesulfonamide(1:1)SumatriptanSuccinate>Penehyclidine Impurity 9SUMATRIPTANSUCCINATE(1:1)SuMatriptan Succinate, EP
J8BDZ68989CHEBI:64359DTXSID60145966ZecuityImigran subjectMigraleve ultraMigraine PackImigran 50

物性

構造計算による物性補完中

極性表面積
148 Ų
水素結合供与体数
4
水素結合受容体数
8
回転可能結合数
9
重原子数
28
形式電荷
0
複雑度
498

実験および物理化学的性質

Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Triptans; Vasoconstrictor Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

物理化学的性質

融点
165 · 165-166°C
貯蔵温度
-20 °C · -20°C
溶解性
2 O: · H2O: >20mg/mL
外見
個体
色
ホワイトからオフホワイト
Merck
14 · 14,8997
BCS Class
3 · 3
主な用途
医薬品(低分子化合物)
InChI
1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
InChIKey
PORMUFZNYQJOEI-UHFFFAOYSA-N
SMILES
OC(=O)CCC(O)=O.CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
CAS データベース
103628 · 103628-48-4(CAS DataBase Reference)

化学的性質

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H318 (79.6%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

P203, P264+P265, P273, P280, P305+P354+P338, P317, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 54 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationSumatriptan succinate: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesEye Dam. 1 (79.6%)

毒性情報

Exposure RoutesSubcutaneous, Oral, Nasal, Transdermal
Toxicity Summary · 1 件

The 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Sumatriptan also blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve.

Signs and Symptoms

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme. Route of Elimination: Only 3% of the dose is excreted in the urine as unchanged sumatriptan; 42% of the dose is excreted as the major metabolite, the indole acetic acid analogue of sumatriptan. Half Life: 2.5 hours

FDA Pharmacological Classification · 2 件

SUMATRIPTAN SUCCINATE

Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]; Serotonin 1d Receptor Agonists [MoA]; Serotonin 1b Receptor Agonists [MoA]

MeSH Pharmacological Classification · 2 件

Drugs used to cause constriction of the blood vessels.

Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.

用途と製造

UsesFor the treatment of migraine attacks with or without aura.
応用分野 · 2 件

説明Sumatriptan succinate is a highly selective 5HT1-like receptor agonist introduced as a new treatment for migraine. It is indicated for the acute relief of migraine and cluster headache. Oral administration is reported to be free of substantial side effects. The compound appears to be a significant advance over the use of ergotamine and other agents in the treatment of migraine.

使用Sumatriptan Succinate is a selective 5-HT1B/1D-receptor agonist with anticonvulsant properties (1,2). Sumatriptan Succinate is used for migraine relief (2).

上流・下流製品情報

上流原料

関連反応

2 件
反応記録を作成
HRID 1625661 の反応式
HRID 1625661反応物としてuspto-grants-2014_07
HRID 1797389 の反応式
HRID 1797389生成物としてuspto-grants-2006_04

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
103628-48-4
PubChem CID
59772
DTXSID
DTXSID60145966
ChEMBL
CHEMBL1201150
ChEBI
CHEBI:64359
UNII
J8BDZ68989
EC Number
600-463-4

化学的特性White Crystalline Powder

Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sumatriptan succinate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
rtecs
EJ9940000
ridadr
3077
hs_code
29350090
risk_code
36/37/38-41
hazard_code
Xi
safety_code
26-36-39
Hazard Classifications
Aquatic Chronic 3Repr. 2
ストレージクラス
11 - Combustible Solids
4-Hydrazino-N-Methyl Benzene Methane Sulphonamide Hydrochloride

下流製品

スマトリプタン
補足説明 · 1 件

定義ChEBI: A succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatm nt of migraine with or without aura in adults.